RMD RESMED INC Insider Trading

CEO Michael J. Farrell sells 4,991 RMD shares at $218.55 under scheduled 10b5-1 plan; retains 466,223 shares plus 19,966 options

Michael J. Farrell executed a scheduled sale of 4,991 shares (5.0K shares) at $218.55 on 2026-07-07 under a pre-arranged 10b5-1 trading plan adopted on 2024-10-31, reducing his non-derivative holdings from 471,214 shares to 466,223 shares (-1.1% vs pre-transaction holdings). The transaction is non-discretionary and reflects an ongoing execution schedule rather than a discretionary trading decision. Farrell retains substantial equity exposure through 466,223 non-derivative shares and an additional 19,966 stock options, maintaining a material ownership position. The stock currently trades at $205.84, down -29.9% from the 52-week high of $293.81 and up +6.6% over the past 30 days.

CEO Michael J. Farrell sold 4,991 shares of RMD at $193.96 via pre-arranged 10b5-1 plan; 466.3K shares remain post-trade.

Michael J. Farrell, Chairman and CEO, sold 4,991 shares on 2026-06-08 at $193.96 as part of a pre-arranged 10b5-1 trading plan adopted on 2024-10-31—a scheduled, non-discretionary transaction. His holdings after the sale total 466.3K shares, a 1.1% reduction from pre-transaction holdings of 471.2K shares, with an additional 24,957 shares in derivative holdings remaining. The stock has declined 33.2% from its 52-week high of $293.81 and is down 5.0% over the past 30 days and 18.2% over 90 days. His prior four trades at RMD over the preceding two months showed consistently negative 30- and 90-day returns (ranging from -5.7% to -12.3% at 30 days, and -7.1% to -24.5% at 90 days), suggesting the stock's recent weakness predates this transaction. Given the planned nature of the sale and the company's solid fundamentals—including $1.4B in quarterly revenue, $398.7M net income, and 9.8% annual growth—this transaction reflects execution of a pre-existing schedule rather than a discretionary response to current market conditions.

CEO Michael Farrell exercises stock options and immediately sells full position; mixed timing history raises questions amid recent stock weakness.

Michael Farrell, ResMed's Chairman and CEO, exercised stock options on the same day and immediately sold the entire position, a classic cashout pattern that reflects no conviction in the stock at current levels. The timing is notable: the stock has declined significantly from its 52-week high and is trading near its 52-week low, yet Farrell chose to exit rather than hold. His prior five sales at ResMed show mixed results—four were well-timed as the stock subsequently declined, but one saw the stock rise afterward—suggesting his sales have captured some downside but without a consistent edge. This marks his 31st open-market sale in the past three years with zero open-market purchases, indicating a long-running pattern of liquidating equity rather than accumulating it. ResMed remains profitable with growing revenue and a reasonable valuation, but the combination of near-52-week-low pricing and the CEO's immediate full exit following an option exercise suggests he saw the current level as an opportunity to monetize rather than a window to increase his stake.

RMD Chairman/CEO Farrell sold 4,991 shares at $225.50; stock now -22.4% from 52-week high, -7.7% in 30 days

Michael J. Farrell, as Chairman and CEO, sold 4,991 shares at $225.50 on 2026-04-07, reducing his holdings from 471,214 to 466,223 shares. The sale occurred as RMD trades -22.4% below its 52-week high and has declined -7.7% over 30 days and -9.7% over 90 days. Farrell's cross-ticker track record shows modest timing results: a 90-day well-timed rate of 38.89% across his 20 prior sells, but at RMD specifically, only 1 of 3 measurable sells (33%) resulted in negative 90-day returns—indicating weaker predictive timing at this ticker. The company fundamentals remain solid (revenue $1.4B, net income $392.6M, P/E 22.35, annual revenue growth +9.8%), so this sale occurs against stable operational backdrop rather than deteriorating performance.

RMD CEO Farrell sells 5.0K shares at $251.03; stock down 18.2% from 52-week high, down 13.0% in 30 days.

Chairman and CEO Michael J. Farrell sold 4,991 shares of RESMED INC (RMD) at $251.03 on 2026-03-09, reducing holdings from 471,214 to 466,223 shares. The sale occurred as RMD trades 18.2% below its 52-week high and has declined 13.0% over the past 30 days. Among Farrell's prior five trades at RMD, timing outcomes are mixed: 1 of 3 prior sells with measurable 90-day outcomes achieved negative returns (well-timed), while another posted -11.7% 30-day decline followed by -13.2% 90-day decline. His broader cross-ticker track record shows a 90-day well-timed rate of 38.89%, indicating sells are timed below average. The company's fundamentals remain solid with annual revenue growth of +9.8% and a P/E of 23.54, though the recent price decline warrants monitoring relative to near-term momentum.

CEO Farrell sells 4,991 shares of RMD at $273.78; holdings drop to 466.2K shares (-1.1%)

Farrell Michael J., Chairman and CEO, sold 4,991 shares of RESMED INC (RMD) at $273.78 on 2026-02-09, reducing his holdings to 466.2K shares. The sale occurred at a price $10.24 above the current market price of $263.54, and within 10.3% of the 52-week high of $293.73. His cross-ticker track record shows a 90-day well-timed rate of 38.89% across 20 prior sells, while at RMD specifically, 2 of 3 measurable prior sales (on 2025-11-07 and 2025-10-07) showed negative 90-day returns, indicating well-timed exits before stock declines. The sale represents a modest portfolio reduction of only 1.1%, consistent with a pattern of regular trimming activity rather than a material confidence shift, given RMD's strong fundamentals (revenue $1.4B, net income $392.6M, annual growth +9.8%, P/E 25.84).

RMD CEO Michael Farrell sells 4,991 shares at $248.46; retains 466,223 shares post-transaction.

CEO Michael Farrell sold 4,991 shares of ResMed for $1,240,065.36 on 2026-01-07, representing a 1.1% reduction from his pre-transaction holdings of 471,214 shares. The sale occurred at $248.46 per share, which stands 14.6% below the 52-week high of $293.73 and 1.8% above the 30-day average performance. Examining his same-ticker history, Farrell's prior three measurable sales at RMD were well-timed at the 90-day mark, with negative returns of -13.2%, -7.8%, and -12.3% respectively. His cross-ticker track record shows a 38.89% well-timed sell rate across 20 prior open-market sales, with an average 90-day return of 7.0%, indicating sales preceded gains rather than declines. This transaction, modest in scale relative to his remaining stake, occurs as ResMed trades near mid-range valuation levels (P/E of 25.47) with recent quarterly net income of $348,536,000.00 on revenue of $1,335,582,000.00.

RMD Chairman and CEO Michael J. Farrell sold 4,991 shares at $251.41 (5.0K shares, $1.3M); stock down 16.1% from 52-week high.

Michael J. Farrell, Chairman and CEO of ResMed Inc., sold 4,991 shares at $251.41 on 2025-12-08, reducing his holdings from 471,214 to 466,223 shares (a -1.1% reduction). The stock has declined 16.1% from its 52-week high of $293.73 and currently trades at $246.52, below the transaction price. Looking at Farrell's prior RMD-specific trading activity, 2 of 3 measurable 90-day outcomes on prior sales were well-timed (stock fell after he sold), but his most recent prior sale on 2025-10-07 showed a -11.7% 30-day return, suggesting recent sales have not preceded gains. His cross-ticker track record shows a 33.33% well-timed rate with an 8.7% average 90-day return after prior sells, indicating his sales across all tickers historically preceded stock declines only one-third of the time. The company itself shows solid fundamentals—$1.3B in latest quarterly revenue, $348.5M net income, 9.8% annual revenue growth, and a market cap of $36.0B—but the recent price weakness and the mix of timing outcomes in his trading pattern warrant attention.

RMD Chair/CEO Farrell sells 8,011 shares at $249.75; stock down 14.8% from 52-week high, 8.0% in 30 days

Michael J. Farrell, Chairman and CEO of ResMed, sold 8,011 shares at $249.75 on 2025-11-07, reducing his holdings by 1.7% to 467,866 shares and generating $2,000,772.89 in proceeds. The sale occurred as RMD has declined 8.0% over the prior 30 days and 11.7% over 90 days, placing it 14.8% below its 52-week high. Examining his same-ticker history at RMD, Farrell's prior five sales show mixed timing outcomes: his most recent sale on 2025-10-07 was followed by a 30-day decline of 11.7%, while earlier sales in August and June were followed by 90-day declines and gains respectively, with only 1 of 3 measurable 90-day outcomes being well-timed (negative return after sale). This modest same-ticker track record, combined with the stock's current downward momentum and elevated valuation (P/E 25.39), provides limited directional clarity on insider sentiment.

CFO Brett Sandercock sells 3,000 RMD shares at $247.54; stock -11.6% in 30 days, -12.1% in 90 days.

Brett Sandercock, the Chief Financial Officer, sold 3,000 shares of ResMed (RMD) at $247.54 on 2025-11-03, reducing his holdings from 88.7K to 85.7K shares. Since the sale, the stock has declined -11.6% over 30 days and -12.1% over 90 days, now trading at $246.40, which is -16.1% from its 52-week high. His prior RMD sales show mixed timing: only 1 of 3 measurable 90-day outcomes was well-timed (negative return after sale), and his most recent RMD sell on 2025-10-01 was followed by a -10.0% 30-day decline while an earlier sell on 2025-05-22 was poorly timed with the stock rising +18.2% thereafter. The company's fundamentals remain solid with $1.3B quarterly revenue, +9.8% annual growth, and $348.5M net income, but the stock's significant recent weakness may warrant tracking whether this represents data-point discretionary selling or a broader reassessment of valuation near a 52-week peak.